Active Substance: Citalopram (as HBr).
Overview
Welcome to Dwaey, specifically on LOPRAM 20 page.
This medicine contains an important and useful components, as it consists of
Citalopram (as HBr)is available in the market in concentration
Citalopram Hydrobromide
Caution should be taken in patients with epilepsy, concurrent electroconvulsive therapy, history of mania, cardiac disease, diabetes mellitus, angle-closure glaucoma, history of bleeding disorders, hepatic and renal impairment. Abrupt withdrawal of Citalopram should be avoided. Gradual discontinuation of treatment if patient enters into manic phase; pregnancy. Increased risk of hyponatraemia and SIADH. May reduce convulsant threshold thus, citalopram should be used with care in epileptic patients. Lactation: Excreted in breast milk; use caution
Depressive illness, Bipolar disorder, Panic disorder, Substance abuse disorders, Alcohol dependence, Anxiety disorders including obsessive-compulsive disorder and social phobia, Post-traumatic stress disorder, Premenstrual syndrome, Idiopathic Parkinson's disease and Eating disorder.
Hypersensitivity, concomitant admin with MAOIs or within 14 days of discontinuing MAOI treatment; children and adolescents <18 yr; treatment of depressive illness; lactation.
>10% Dry mouth (20%),Nausea (21%),Somnolence (18%),Insomnia (15%),Xerostomia (20%),Increased sweating (11%) 1-10% Tremor (8%),Diarrhea (8%),Ejaculation disorder (6%),Rhinitis (5%),Upper respiratory infection (5%),Dyspepsia (5%),Fatigue (5%),Vomiting (4%),Anxiety (4%),Anorexia (4%),Abdominal pain (3%),Agitation (3%),Impotence (3%),Sinusitis (3%),Dysmenorrhea (3%),Decreased libido (2%),Yawning (2%),Arthralgia (2%),Myalgia (2%),Amenorrhea (>1%),Confusion (>1%),Cough (>1%),Flatulence (>1%),Increased saliva (>1%),Migraine (>1%),Orthostatic hypotension (>1%),Paresthesia (>1%),Polyuria (>1%),Pruritus (>1%),Rash (>1%),Tachycardia (>1%),Weight change (>1%) Potentially Fatal: Increased risk of suicidal thinking and behaviour especially in child and adolescents. Monitor closely for signs of clinical worsening, suicidality or unusual changes in behaviour.
3
Citalopram is bicyclic phthalane derivative and a selective serotonin re-uptake inhibitor, w/ little or no effect on noradrenaline, dopamine and GABA re-uptake. The inhibitory activity explains the antidepressant property of citalopram. It has no or very low affinity for 5-HT1AA, 5-HT2A, D1 and D2 receptors, alpha 1, alpha2, beta-adrenergic, histamine H1, muscarinic, cholinergic, benzodiazepine and opioid receptors.
May increase anticoagulant effect w/ drugs affecting haemostatis (e.g. warfarin). Increased risk of hypomania w/ sibutramine. Increased lowering seizure threshold w/ TCAs and other SSRIs. Potentially Fatal: Increased risk of severe adverse effects (e.g. serotonin syndrome) w/ MAOI. QT interval prolongation w/ subsequent risk of torsade de pointes w/ QT-prolonging drugs (e.g. pimozide, quinidine, procainamide, chlorpromazine, thioridazine, amiodarone, sotalol, moxifloxacin, pentamidine, levomethadyl, methadone).
Information not available